{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:08:18Z","timestamp":1772136498980,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Young talents of Yunnan Xingdian Talents Support Program","award":["XDYC-QNRC-2023-0189"],"award-info":[{"award-number":["XDYC-QNRC-2023-0189"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-86655-y","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T14:57:23Z","timestamp":1743433043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors affecting prognosis in patients with locally advanced and advanced esophageal cancer receiving definitive radiotherapy in plateau regions"],"prefix":"10.1038","volume":"15","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoxiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"3","key":"86655_CR1","first-page":"212","volume":"45","author":"RS Zheng","year":"2023","unstructured":"Zheng, R. S. et al. Cancer statistics in China, 2016. Chin. J. Oncol. 45 (3), 212\u2013219 (2023).","journal-title":"Chin. J. Oncol."},{"key":"86655_CR2","first-page":"188","volume":"91","author":"DI Garrido","year":"2018","unstructured":"Garrido, D. I. & Garrido, S. M. Cancer risk associated with living at high altitude in Ecuadorian population from 2005 to 2014. Clujul Med. 91, 188\u2013196 (2018).","journal-title":"Clujul Med."},{"key":"86655_CR3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1134\/S0006297921100011","volume":"86","author":"DS Dzhalilova","year":"2021","unstructured":"Dzhalilova, D. S. & Makarova, O. V. HIF-dependent mechanisms of relationship between hypoxia tolerance and tumor development. Biochemistry (Mosc). 86, 1163\u20131180 (2021).","journal-title":"Biochemistry (Mosc)"},{"key":"86655_CR4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.18632\/oncoscience.272","volume":"2","author":"KM Dodd","year":"2015","unstructured":"Dodd, K. M. & Tee, A. R. STAT3 and mTOR: Co-operating to drive HIF and angiogenesis. Oncoscience 2, 913\u2013914 (2015).","journal-title":"Oncoscience"},{"key":"86655_CR5","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.3390\/cancers15225421","volume":"15","author":"CP Pai","year":"2023","unstructured":"Pai, C. P., Chien, L. I., Huang, C. S., Hsu, H. S. & Hsu, P. K. Treatment outcomes and risk factors for incomplete treatment after definitive chemoradiotherapy for non-resectable or metastatic esophageal cancer. Cancers (Basel). 15, 5421 (2023).","journal-title":"Cancers (Basel)"},{"key":"86655_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dow033","volume":"30","author":"MP van Ruler","year":"2017","unstructured":"van Ruler, M. P. et al. Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Dis. Esophagus. 30, 1\u20139 (2017).","journal-title":"Dis. Esophagus"},{"key":"86655_CR7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00423-022-02445-4","volume":"407","author":"N Tsuchiya","year":"2022","unstructured":"Tsuchiya, N. et al. Chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Langenbecks Arch. Surg. 407, 1911\u20131921 (2022).","journal-title":"Langenbecks Arch. Surg."},{"key":"86655_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2015.07.011","volume":"116","author":"P Zhang","year":"2015","unstructured":"Zhang, P. et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother. Oncol. 116, 257\u2013261 (2015).","journal-title":"Radiother. Oncol."},{"key":"86655_CR9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato, K. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 1506\u20131517 (2019).","journal-title":"Lancet Oncol."},{"key":"86655_CR10","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima, T. et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138\u20134148 (2020).","journal-title":"J. Clin. Oncol."},{"key":"86655_CR11","unstructured":"Guan, R. Bioinformatics Study of Hypoxia and Immunosuppressive Microenvironment in Colorectal cancer (Shantou University, 2022)."},{"key":"86655_CR12","doi-asserted-by":"crossref","unstructured":"Chen, P. Identification of Hypoxia-Associated Signature in Colon Cancer to Assess Tumor Immune Microenvironment and Predict Prognosis Based on 14 Hypoxia-Associated Genes (Hebei Medical University, 2023).","DOI":"10.2147\/IJGM.S407005"},{"key":"86655_CR13","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458\u20135468 (2014).","journal-title":"Cancer Res."},{"key":"86655_CR14","doi-asserted-by":"crossref","first-page":"786429","DOI":"10.3389\/fimmu.2021.786429","volume":"12","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. Spatial distribution and predictive significance of dendritic cells and macrophages in esophageal cancer treated with combined chemoradiotherapy and PD-1 blockade. Front. Immunol. 12, 786429 (2022).","journal-title":"Front. Immunol."},{"issue":"34","key":"86655_CR15","first-page":"1","volume":"19","author":"X Liu","year":"2022","unstructured":"Liu, X. Effect of immunotherapy combined with targeted therapy on serum HIF-1\u03b1, VEGF, AFP and PHD2 levels in patients with advanced liver cancer. Med. Innov. China. 19 (34), 1\u20134 (2022).","journal-title":"Med. Innov. China"},{"key":"86655_CR16","doi-asserted-by":"crossref","first-page":"1060695","DOI":"10.3389\/fimmu.2022.1060695","volume":"13","author":"H Wei","year":"2022","unstructured":"Wei, H. et al. Comparison of dynamic changes in the peripheral CD8\u2009+\u2009T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy. Front. Immunol. 13, 1060695 (2022).","journal-title":"Front. Immunol."},{"key":"86655_CR17","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1002\/cam4.3409","volume":"9","author":"J Lyu","year":"2020","unstructured":"Lyu, J. et al. Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China. Cancer Med. 9, 7460\u20137468 (2020).","journal-title":"Cancer Med."},{"key":"86655_CR18","first-page":"889","volume":"43","author":"XM Wang","year":"2021","unstructured":"Wang, X. M. et al. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: A multicenter retrospective data analysis (3JECROG R-05)]. Zhonghua Zhong Liu Za Zhi. 43, 889\u2013896 (2021).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"86655_CR19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10388-022-00930-9","volume":"19","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Factors affecting the completion of concurrent chemotherapy and impact of non-completion on survival in locally advanced esophageal squamous cell carcinoma. Esophagus 19, 717\u2013725 (2022).","journal-title":"Esophagus"},{"key":"86655_CR20","unstructured":"Ren, X. J.  A Study of Barium Swallow Combined with CT to Evaluate the short-term Efficacy of Radiotherapy for Esophageal cancer (Hebei Medical University, 2012)."},{"key":"86655_CR21","unstructured":"Han, C. Discussion on the new criteria for the evaluation of short-term efficacy after radiotherapy for esophageal cancer. In Radiation Oncology Committee of Chinese Anti-Cancer Association, Sino-American Radiation Oncology Association (SANTRO).Academic Conference of the Academic Conference of the Chinese Anti-Cancer Association (SANTRO) 2012 Jinan International Radiation Oncology Forum (2012)."},{"key":"86655_CR22","first-page":"641","volume":"49","author":"Chinese Society of Clinical Oncology Radiotherapy Committee, Chinese Medical Association Radiotherapy Oncology Branch, & Chinese Anti-Cancer Association Radiation Oncology Branch","year":"2022","unstructured":"Chinese Society of Clinical Oncology Radiotherapy Committee, Chinese Medical Association Radiotherapy Oncology Branch, & Chinese Anti-Cancer Association Radiation Oncology Branch. Guidelines for radiotherapy of esophageal cancer in China (2022 edition). Int. J. Oncol. 49, 641\u2013657 (2022).","journal-title":"Int. J. Oncol."},{"issue":"34","key":"86655_CR23","doi-asserted-by":"crossref","first-page":"e34647","DOI":"10.1097\/MD.0000000000034647","volume":"102","author":"HC Luo","year":"2023","unstructured":"Luo, H. C. et al. Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma. Medicine 102 (34), e34647 (2023).","journal-title":"Medicine"},{"key":"86655_CR24","doi-asserted-by":"crossref","first-page":"960339","DOI":"10.3389\/fimmu.2023.960339","volume":"14","author":"S Xu","year":"2023","unstructured":"Xu, S., Xu, X. & Zhu, H. Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma. Front. Immunol. 14, 960339 (2023).","journal-title":"Front. Immunol."},{"key":"86655_CR25","doi-asserted-by":"crossref","first-page":"936684","DOI":"10.3389\/fonc.2022.936684","volume":"12","author":"W Ni","year":"2022","unstructured":"Ni, W. et al. Severe radiation-induced lymphopenia during postoperative radiotherapy or chemoradiotherapy has poor prognosis in patients with stage IIB-III after radical esophagectomy: a post hoc analysis of a randomized controlled trial. Front. Oncol. 12, 936684 (2022).","journal-title":"Front. Oncol."},{"issue":"13","key":"86655_CR26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.21037\/atm-22-2669","volume":"10","author":"Q Zhao","year":"2022","unstructured":"Zhao, Q. et al. Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: A retrospective analysis. Ann. Transl. Med. 10 (13), 744 (2022).","journal-title":"Ann. Transl. Med."},{"key":"86655_CR27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky, B. D. et al. INT 0123 (Radiation Therapy Oncology Group 94\u2009\u2013\u200905) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J. Clin. Oncol. 20, 1167\u20131174 (2002).","journal-title":"J. Clin. Oncol."},{"key":"86655_CR28","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","volume":"39","author":"MCCM Hulshof","year":"2021","unstructured":"Hulshof, M. C. C. M. et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J. Clin. Oncol. 39, 2816\u20132824 (2021).","journal-title":"J. Clin. Oncol."},{"key":"86655_CR29","doi-asserted-by":"crossref","first-page":"1971418","DOI":"10.1080\/2162402X.2021.1971418","volume":"10","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: A phase 1b study. Oncoimmunology 10, 1971418 (2021).","journal-title":"Oncoimmunology"},{"key":"86655_CR30","doi-asserted-by":"crossref","first-page":"e19785","DOI":"10.1371\/journal.pone.0019785","volume":"6","author":"HJ Sung","year":"2011","unstructured":"Sung, H. J. et al. Ambient oxygen promotes tumorigenesis. PLoS One. 6, e19785 (2011).","journal-title":"PLoS One"},{"key":"86655_CR31","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1172\/JCI137554","volume":"130","author":"SM Hatfield","year":"2020","unstructured":"Hatfield, S. M. & Sitkovsky, M. V. Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy. J. Clin. Invest. 130, 5629\u20135637 (2020).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"86655_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1440-1681.12693","volume":"44","author":"JP Sch\u00f6ning","year":"2017","unstructured":"Sch\u00f6ning, J. P., Monteiro, M. & Gu, W. Drug resistance and cancer stem cells: The shared but distinct roles of hypoxia-inducible factors HIF1\u03b1 and HIF2\u03b1. Clin. Exp. Pharmacol. Physiol. 44 (2), 153\u2013161 (2017).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"86655_CR33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ijc.34030","volume":"151","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial. Int. J. Cancer. 151, 607\u2013615 (2022).","journal-title":"Int. J. Cancer"},{"key":"86655_CR34","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1038\/s41467-021-24288-1","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: A randomized phase II trial. Nat. Commun. 12, 4014 (2021).","journal-title":"Nat. Commun."},{"issue":"6","key":"86655_CR35","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.21037\/jgo-22-1196","volume":"13","author":"W Lin","year":"2022","unstructured":"Lin, W. et al. Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: A retrospective, single-center, three-arm study. J. Gastrointest. Oncol. 13 (6), 2758\u20132768 (2022).","journal-title":"J. Gastrointest. Oncol."},{"issue":"9","key":"86655_CR36","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.21037\/jtd-22-402","volume":"14","author":"C Li","year":"2022","unstructured":"Li, C. et al. Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC). J. Thorac. Dis. 14 (9), 3277\u20133284 (2022).","journal-title":"J. Thorac. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86655-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T14:58:26Z","timestamp":1743433106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86655"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86655-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5006934\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Yunnan Cancer Hospital (approval number: KYLX2024-029). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"11017"}}